Feeding Premature Infants During Non-invasive Respiratory Support

Feeding Very-low-birth-weight (VLBW) Premature Infants (<1500g) During Non-invasive Respiratory Support- Continuous Drip Vs. Bolus Gavage Feeding

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03852641

Enrollment

100

Registered

2019-02-25

Start date

2017-10-01

Completion date

2022-06-30

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-invasive Respiratory Support, Premature Infant

Brief summary

A randomized control trial comparing bolus gavage feeds to continuous feed among premature infants supported by non-invasive respiratory support

Interventions

OTHERLength of feeding

Feeds will be given via nasogastric tube over 15-30 min versus 2 hr

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Infants \<1500gr, on non-invasive respiratory support * Feeding\>20 ml/kg/day

Exclusion criteria

* Major congenital malformations * Unstable infants because of sepsis, central nervous system, cardiac or other significant morbidities * Gastrointestinal morbidity such as spontaneous intestinal perforation (SIP) and necrotising enterocolitis (NEC).

Design outcomes

Primary

Measure	Time frame
Oxygenation instability as documented by oxygen saturation histograms	before dischatge home at an average of 40 weeks gestation
Time to full feeds (TFF) defined as full enteral gavage feeding of 150 cc/Kg/day	before dischatge home at an average of 40 weeks gestation

Secondary

Measure	Time frame
Respiratory-length of respiratory support	before dischatge home at an average of 40 weeks gestation
Incidence of Necrotising enterocolitis (NEC) as defined by the medical team	before dischatge home at an average of 40 weeks gestation

Countries

Israel

Contacts

Primary ContactLiron Borenstein-Levin, MD

liron.boren@gmail.com04-7774125

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026